record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
accepted
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding type[object Object] · [object Object] · [object Object] · [object Object]
evidence
source-boundexperimental · manual state transition; placebo-controlled clinical trial where source reports control arm · Homo sapiens
proof impact
packet context2 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition; placebo-controlled clinical trial where source reports control arm
evidence type
experimental
species
Homo sapiens
evidence spans
Verubecestat (BACE1 inhibitor) Phase III EPOCH trial in mild-moderate AD halted for futility; cognitive worsening signal observed. Production-side amyloid intervention failed alongside MAb clearance approaches, narrowing therapeutic-window viability of the amyloid hypothesis.
Michael Egan; James Kost; Pierre N. Tariot; Paul Aisen; Jeffrey L. Cummings; Bruno Vellas; Cyrille Sur; Yuki Mukai. New England Journal of Medicine 2018. doi:10.1056/NEJMoa1706441 · curator_source · 10.1056/NEJMoa1706441
conditions
Provenance
source title
Michael Egan; James Kost; Pierre N. Tariot; Paul Aisen; Jeffrey L. Cummings; Bruno Vellas; Cyrille Sur; Yuki Mukai. New England Journal of Medicine 2018. doi:10.1056/NEJMoa1706441
doi
10.1056/NEJMoa1706441
pmid
29719179
journal
New England Journal of Medicine
authors
Michael Egan, James Kost, Pierre N. Tariot, Paul Aisen, Jeffrey L. Cummings, Bruno Vellas, Cyrille Sur, Yuki Mukai
source record
declaredvs_10993e8203d14020doi:10.1056/NEJMoa1706441 · 10.1056/NEJMoa1706441
inspect source →
source record
declaredvs_e1be38b966c19185doi:10.1056/NEJMoa1706441 · 10.1056/NEJMoa1706441 · 29719179
inspect source →
Verubecestat (BACE1 inhibitor) Phase III EPOCH trial in mild-moderate AD halted for futility; cognitive worsening signal observed. Production-side amyloid intervention failed alongside MAb clearance approaches, narrowing therapeutic-window viability of the amyloid hypothesis.
vs_e1be38b966c19185 · source:Michael Egan; James Kost; Pierre N. Tariot; Paul Aisen; Jeffrey L. Cummings; Bruno Vellas; Cyrille Sur; Yuki Mukai. New England Journal of Medicine 2018. doi:10.1056/NEJMoa1706441|section:curator_source · manual_curation
outgoing
No outgoing links.
incoming
No incoming links.
events
vev_02998164eba87654finding.reviewedVerubecestat EPOCH (Egan et al., NEJM 2018) and APECS were halted for futility, establishing BACE1 inhibition as a failed translation arm. The failed-trial finding is well-supported. Agent-drafted accept; eligible for human re-review.
agent:vela-curation-bot-2026-05-09 · 2026-05-09
vev_7100374369c4dbe5finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_02cc6836a2d1d57ffinding.reviewVerubecestat EPOCH (Egan et al., NEJM 2018) and APECS were halted for futility, establishing BACE1 inhibition as a failed translation arm. The failed-trial finding is well-supported. Agent-drafted accept; eligible for human re-review.
applied · agent:vela-curation-bot-2026-05-09 · 2026-05-09
vpr_81c389ba7649fe21finding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation record targets this finding id.